Galena Biopharma, Inc. (NASDAQ:GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced the completion of enrollment in the Company’s Phase 2a clinical trial for GALE-301, or Folate Binding Protein (FBP) peptide immunotherapy. Galena Biopharma Inc (NASDAQ:GALE) weekly performance is -2.56%. On last trading day company Insys Therapeutics Inc (NASDAQ:INSY) shares ended up $3.05. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is 30.06%.
On June 16, 2014 — Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, announced that it has received premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx™ System Sequenom, Inc. (NASDAQ:SQNM) shares advanced 7.78% in last trading session and ended the day on $3.60. Gross Margin is 38.70% and its return on assets is -59.90%. Sequenom, Inc. (NASDAQ:SQNM) quarterly performance is 54.51%.
On June 13, Pomerantz LLP announces the filing of a class action lawsuit against INSYS Therapeutics, Inc. (NASDAQ:INSY)and certain of its officers. The class action, filed in United States District Court, District of Arizona, and docketed under 2:14-cv-01043-GMS, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of INSYS between May 1, 2013 and May 8, 2014, both dates inclusive (the “Class Period”). Insys Therapeutics Inc (NASDAQ:INSY) shares moved up 12.29% in last trading session and was closed at $29.70, while trading in range of $26.50 – $30.81. Insys Therapeutics Inc (NASDAQ:INSY) year to date (YTD) performance is 15.07%.
On June 7, Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 760,879 shares, a decline of 20.7% from the April 30th total of 959,903 shares, AR Network reports. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) ended the last trading day at $18.75. Company weekly volatility is calculated as 8.97% and price to cash ratio as 2.49. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) showed a negative weekly performance of -5.45%.
There is a significant amount of interest shown by investors on the shares of the clinical stage biotechnology company Applied Genetic Technologies Corp (NASDAQ:AGTC) in the month of June. The stock had hit yearly high price on June 13. Though there is no big news from the company after the announcement of its financial results for the third quarter, there is a good number of takers for this stock in the current month. Applied Genetic Technologies Corp (NASDAQ:AGTC) weekly performance is 18.11%. On last trading day company shares ended up $29.87. Analysts mean target price for the company is $26.00. Applied Genetic Technologies Corp (NASDAQ:AGTC) distance from 50-day simple moving average (SMA50) is 94.23%.
Leave a Reply